查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1377405

病毒載體和質粒 DNA 製造市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品類型、應用、地區和競爭細分

Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Product Type, Application, By Region, and Competition
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球病毒載體和質粒 DNA 製造市場價值為 54.9 億美元，預計在預測期內將出現令人印象深刻的成長，到 2028 年複合CAGR為10.89%。病毒載體和質粒DNA 製造是生物技術和生物製藥的重要流程產業，特別是基因治療、疫苗生產和基因工程等應用。這些過程涉及病毒載體和質粒 DNA 的生產和純化，它們是分子生物學和醫學領域各種應用的重要工具。使用不同類型的病毒載體，例如腺相關病毒 (AAV)、慢病毒、逆轉錄病毒等。選擇取決於具體應用和目標細胞。質粒 DNA (pDNA) 是細菌中發現的環狀雙股 DNA 分子。它通常用於生物技術中的各種目的，包括重組蛋白的生產、基因克隆以及作為基因治療的載體。市場的一個重要推動因素是基因治療研究和開發投資的不斷成長。病毒載體和質粒DNA都是基因治療產品的重要組成部分。開發遺傳性疾病和罕見疾病新療法的潛力吸引了公共和私營部門的大量資金。

生物技術的不斷進步，包括 CRISPR-Cas9 等基因編輯技術，擴大了基因治療的可能性。這推動了對病毒載體和質粒 DNA 所提供的高效、安全的遞送系統的需求。幾種基因療法在臨床試驗中的成功以及隨後獲得 FDA 和 EMA 等監管機構的批准，增強了人們對該領域的信心。這些成功鼓勵了對病毒載體和質粒 DNA 的進一步投資和開發。基因療法提供了高度針對性治療的潛力，可以最大限度地減少副作用並改善患者的治療結果。這種有針對性的方法對於癌症治療和其他複雜疾病特別有吸引力。

主要市場促進因素

市場概況
預測期 2024-2028
2022 年市場規模 54.9億美元
2028 年市場規模 101.4億美元
2023-2028 年CAGR 10.89%
成長最快的細分市場 癌症
最大的市場 北美洲

生物技術的進步

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球病毒載體與質粒 DNA 製造市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型（質粒 DNA、病毒載體和非病毒載體）
    • 按應用（癌症、遺傳性疾病、傳染病和其他應用）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：亞太地區病毒載體與質粒 DNA 製造市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按應用
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國病毒載體與質粒DNA製造
    • 印度病毒載體與質粒 DNA 製造
    • 澳洲病毒載體與質粒 DNA 製造
    • 日本病毒載體與質粒 DNA 製造
    • 韓國病毒載體與質粒 DNA 製造

第 7 章：歐洲病毒載體與質粒 DNA 製造市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按應用
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 8 章：北美病毒載體與質粒 DNA 製造市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按應用
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 9 章：南美洲病毒載體與質粒 DNA 製造市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按應用
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲病毒載體和質粒 DNA 製造市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按應用
    • 按國家/地區
  • MEA：國家分析
    • 南非病毒載體與質粒 DNA 製造
    • 沙烏地阿拉伯病毒載體與質粒 DNA 製造
    • 阿拉伯聯合大公國病毒載體與質粒 DNA 製造

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：全球病毒載體和質粒 DNA 製造市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第 15 章：大環境分析

第16章：競爭格局

  • 牛津生物醫學公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 同源生物服務公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 細胞和基因治療彈射器有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • FinVector 視覺治療
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 富士軟片控股公司（Fujifilm Diosynth Biotechnologies）
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • SIRION 生技有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 默克公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 賽默飛世爾科技公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 獨特的NV
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 康泰倫特公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis

第 17 章：策略建議

關於我們及免責聲明

簡介目錄
Product Code: 16520

Global Viral Vector and Plasmid DNA Manufacturing Market has valued at USD 5.49 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 10.89% through 2028. Viral vector and plasmid DNA manufacturing are essential processes in biotechnology and biopharmaceutical industries, particularly for applications like gene therapy, vaccine production, and genetic engineering. These processes involve the production and purification of viral vectors and plasmid DNA, which serve as crucial tools for various applications in the field of molecular biology and medicine. Different types of viral vectors are used, such as adeno-associated viruses (AAVs), lentiviruses, retroviruses, and others. The choice depends on the specific application and target cells. Plasmid DNA (pDNA) is a circular, double-stranded DNA molecule found in bacteria. It is commonly used in biotechnology for various purposes, including the production of recombinant proteins, gene cloning, and as a vector for gene therapy. A significant driver for the market is the growing investment in gene therapy research and development. Both viral vectors and plasmid DNA are essential components in gene therapy products. The potential to develop novel treatments for genetic and rare diseases has attracted substantial funding from both public and private sectors.

Ongoing advancements in biotechnology, including gene editing techniques like CRISPR-Cas9, have expanded the possibilities for gene therapy. This has driven the need for efficient and safe delivery systems, which viral vectors and plasmid DNA provide. The success of several gene therapies in clinical trials and their subsequent approvals by regulatory agencies, such as the FDA and EMA, have boosted confidence in the field. These successes encourage further investment and development in viral vectors and plasmid DNA. Gene therapies offer the potential for highly targeted treatments, which can minimize side effects and improve patient outcomes. This targeted approach is particularly attractive for cancer treatments and other complex diseases.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 5.49 Billion
Market Size 2028USD 10.14 Billion
CAGR 2023-202810.89%
Fastest Growing SegmentCancer
Largest MarketNorth America

Advancements in Biotechnology

Technologies like CRISPR-Cas9 have revolutionized genetic engineering. They allow precise and efficient modification of genes in various organisms, holding tremendous potential for treating genetic diseases, creating genetically modified organisms (GMOs), and advancing basic research. Advances in genomics have made it possible to sequence entire genomes quickly and cost-effectively. This has paved the way for personalized medicine, where treatments are tailored to an individual's genetic makeup, increasing treatment efficacy, and reducing side effects. The biopharmaceutical industry has grown significantly, producing complex drugs like monoclonal antibodies, vaccines, and gene therapies. Biomanufacturing techniques have improved, leading to more efficient and cost-effective production of these drugs. Synthetic biology involves designing and constructing biological parts, devices, and systems to perform specific functions. This field has led to the creation of synthetic organisms, biosensors, and biofuels. Stem cell research has advanced significantly, leading to the development of stem cell therapies for various diseases and injuries. These therapies have the potential to regenerate damaged tissues and organs. Advances in bioinformatics have enabled the efficient storage, analysis, and interpretation of vast amounts of biological data. This is crucial for genomics, drug discovery, and understanding complex biological processes. Biotechnology is being used to address environmental challenges, such as pollution remediation, waste management, and the development of biofuels and bioplastics.

Genetically modified crops (GMOs) have been developed to improve crop yield, resistance to pests and diseases, and nutritional content. This technology has the potential to enhance food security and sustainability. Biotechnology has led to the development of novel vaccines and immunotherapies for infectious diseases and cancer. These treatments harness the body's immune system to combat diseases. The study of the human microbiome has revealed the crucial role of microorganisms in human health. Advances in microbiome research have implications for understanding and treating various diseases. The integration of nanotechnology with biotechnology has led to the development of nanoparticles and nanoscale tools for drug delivery, imaging, and diagnostics. 3D bioprinting technology allows the fabrication of complex tissues and organs using living cells. This has potential applications in regenerative medicine and tissue engineering. Biotechnology is used to develop biosensors and bioremediation techniques for monitoring and cleaning up environmental pollutants. AI and machine learning are increasingly used to analyze biological data, model biological systems, and assist in drug discovery and development. This factor will help in the development of Global Viral Vector and Plasmid DNA Manufacturing Market.

Increasing Investment in Gene Therapy

Gene therapy involves the introduction of therapeutic genes or genetic material into a patient's cells to treat or prevent disease. Viral vectors and plasmid DNA serve as essential tools for delivering these therapeutic genes into target cells. Viral vectors, such as adeno-associated viruses (AAVs) or lentiviruses, are used for in vivo gene therapy, while plasmid DNA is often employed in ex vivo gene therapy. The development of gene therapies starts with extensive research and preclinical studies. This research phase often involves testing different viral vectors and plasmid DNA constructs to optimize delivery and expression of therapeutic genes. Investment in research drives the demand for these materials. Gene therapies must go through rigorous clinical trials to demonstrate safety and efficacy before they can be approved for widespread use. These trials require substantial quantities of viral vectors and plasmid DNA, especially as they progress to larger patient populations. Once a gene therapy is proven effective in clinical trials, it enters the commercialization phase. This involves scaling up production to meet market demand. Viral vectors and plasmid DNA manufacturers play a critical role in providing the necessary materials for large-scale production.

Gene therapy has a wide range of applications beyond rare genetic diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. The versatility of viral vectors and plasmid DNA makes them suitable for various therapeutic areas, further increasing demand. Regulatory agencies like the FDA in the United States have introduced expedited pathways and designations for promising gene therapies. These pathways encourage investment in gene therapy development and manufacturing. Success stories in gene therapy, such as the approval of Luxturna and Zolgensma, have bolstered investor confidence in the field. Increased funding from both venture capital and pharmaceutical companies fuels the development and manufacturing of viral vectors and plasmid DNA. The demand for gene therapies is not limited to a single region. It is a global market, and as more countries recognize the potential of gene therapy, there is a growing need for a reliable supply of viral vectors and plasmid DNA worldwide. Ongoing advancements in bioprocessing and manufacturing techniques for viral vectors and plasmid DNA are making production more efficient and cost-effective, aligning with the needs of a growing market. Gene therapy offers the potential for transformative treatments, which attracts investment and support from patients, advocacy groups, and healthcare systems. This factor will pace up the demand of Global Viral Vector and Plasmid DNA Manufacturing Market.

Technological Advancements

Single-use bioreactors have gained popularity in biopharmaceutical manufacturing, including viral vector and plasmid DNA production. These disposable systems offer flexibility, reduce the risk of contamination, and decrease setup times compared to traditional stainless-steel bioreactors. Advances in cell culture media and bioprocess optimization have led to higher cell densities and productivity. This results in increased yields of viral vectors and plasmid DNA from bioreactors, reducing production costs. The development of stable and high-yielding cell lines for viral vector and plasmid DNA production has led to more efficient and consistent manufacturing processes. Modified cell lines optimized for specific applications can increase productivity. New chromatography and purification techniques have been developed to enhance the purity and yield of viral vectors and plasmid DNA. Improved resin materials, column designs, and purification strategies contribute to higher product quality. Closed and automated systems minimize the risk of contamination, reduce operator intervention, and increase the reproducibility of manufacturing processes. These systems are particularly important in the production of viral vectors and plasmid DNA for clinical applications. Advances in analytical techniques and quality control methods enable real-time monitoring and characterization of viral vector and plasmid DNA products. This ensures product consistency and helps meet regulatory requirements.

Process Analytical Technology (PAT) tools, including sensors and data analytics, are integrated into manufacturing processes to provide real-time data and enable process control and optimization. This enhances product quality and reduces the need for time-consuming offline testing. Scalable manufacturing platforms are crucial to meet the increasing demand for viral vectors and plasmid DNA. Modular and flexible systems allow for easy scale-up from research and development to commercial production. New platforms and technologies for viral vector production, such as baculovirus-insect cell systems and transient transfection using suspension-adapted cell lines, offer alternatives to traditional adherent cell culture methods. Continuous manufacturing approaches are being explored to replace batch processes in viral vector and plasmid DNA production. Continuous systems offer greater productivity, reduced production time, and smaller facility footprints. Enhanced safety measures, such as containment systems and viral inactivation technologies, have been developed to mitigate the risks associated with handling viral vectors, especially when working with pathogenic viruses. Overall cost reduction strategies, including more efficient use of resources, optimization of raw materials, and improved process yields, contribute to the affordability and accessibility of viral vectors and plasmid DNA products. Manufacturers are increasingly focused on sustainability, exploring eco-friendly materials and processes to reduce the environmental impact of viral vector and plasmid DNA production. This factor will accelerate the demand of Global Viral Vector and Plasmid DNA Manufacturing Market.

Key Market Challenges

Costs and Pricing Pressures

Viral vector and plasmid DNA manufacturing processes can be complex, involving multiple steps and the use of specialized equipment and materials. These processes can be costly to establish and operate, leading to higher production costs. As gene therapies progress from research and development to commercial production, companies face the challenge of scaling up manufacturing processes. Achieving economies of scale while maintaining product quality is a delicate balance that impacts costs. Meeting stringent regulatory requirements for gene therapy products adds additional costs to manufacturing. Companies must invest in quality control, documentation, and compliance measures, which can be resource intensive. Ensuring the safety and efficacy of viral vectors and plasmid DNA products requires rigorous quality control and assurance processes. These processes can increase production costs, especially when addressing deviations or maintaining consistent quality. Building and maintaining state-of-the-art manufacturing facilities and cleanrooms compliant with Good Manufacturing Practices (GMP) standards is a significant upfront investment that can lead to cost pressures. The cost of raw materials, such as cell culture media, growth factors, and purification reagents, can impact overall manufacturing costs. Supply chain disruptions or fluctuations in raw material prices can increase these costs. Proper disposal of waste materials generated during manufacturing, including biological waste and hazardous materials, can be expensive and regulated.

Ethical and Societal Considerations

The ability to modify genes raises concerns about the potential for genetic enhancement and the creation of designer babies. Ethical debates revolve around the boundaries of gene editing and the implications for future generations. Ensuring that patients fully understand the risks and benefits of gene therapy is crucial. Obtaining informed consent from patients and, in some cases, their families or guardians, can be challenging, especially when dealing with vulnerable populations. There are concerns about equitable access to gene therapies. High costs can limit access to these treatments, potentially exacerbating health disparities. Ensuring affordability and accessibility for all patients is an ethical imperative. Gene therapies are relatively new, and their long-term safety and efficacy are not always well-understood. Ethical considerations include the need for ongoing monitoring and the obligation to report adverse events. Editing the germline (sperm and egg cells) raises significant ethical questions. Permanent genetic changes made to the germline can be passed on to future generations, potentially altering the human gene pool. Obtaining informed consent for germline editing is particularly complex, as the implications extend to descendants who cannot provide consent. Global discussions are ongoing to establish guidelines and regulations for such interventions. Gene editing techniques can sometimes have unintended "off-target" effects, potentially causing harm. Ethical considerations include the need to minimize off-target effects and disclose any risks to patients.

Key Market Trends

Cell and Gene Therapy Ecosystem Development

Collaboration among academic institutions, research organizations, and biopharmaceutical companies is crucial for advancing cell and gene therapy technologies. These partnerships enable the exchange of knowledge, expertise, and resources, accelerating the development of innovative therapies. Many countries have established specialized research centers and institutes dedicated to cell and gene therapy research. These centers serve as hubs for cutting-edge research and provide a nurturing environment for scientists and innovators. Biotechnology clusters or hubs, often located in regions with a strong biotech presence, foster innovation, collaboration, and investment in cell and gene therapy. Examples include the Boston-Cambridge area in the United States and the Golden Triangle in the United Kingdom. Governments and private entities are providing funding and grants to support cell and gene therapy research and development. These initiatives help attract top talent and stimulate innovation in the field. Regulatory agencies are actively engaged in shaping policies and pathways for cell and gene therapies. They provide guidance, expedited review processes, and incentives to facilitate product development and approvals. Investments in manufacturing facilities and infrastructure that meet Good Manufacturing Practices (GMP) standards are essential. This includes the construction of specialized cell and gene therapy manufacturing plants. Patient advocacy organizations and support groups play a vital role in advancing cell and gene therapies. They raise awareness, advocate for patients' needs, and provide valuable insights to researchers and developers. Venture capital firms and investors are increasingly interested in funding cell and gene therapy startups. This investment activity drives innovation and entrepreneurship in the ecosystem.

Segmental Insights

Product Type Insights

In 2022, the Global Viral Vector and Plasmid DNA Manufacturing Market largest share was held by Plasmid DNA segment and is predicted to continue expanding over the coming years. Plasmid DNA is used in various applications beyond gene therapy, including vaccine development, protein expression, and research purposes. This versatility allows it to have a broader market reach and more diverse customer base compared to viral vectors, which are primarily used in gene therapy. Plasmid DNA plays a crucial role in the development of DNA-based vaccines, which have gained attention due to their potential in preventing infectious diseases. The COVID-19 pandemic led to increased demand for DNA vaccines, boosting the plasmid DNA manufacturing market. Many biopharmaceutical and biotech companies already have established infrastructure and expertise for plasmid DNA production, making it a convenient choice for in-house research and development.

Application Insights

In 2022, the Global Viral Vector and Plasmid DNA Manufacturing Market cancer segment to witness robust growth in the forecast period and is predicted to continue expanding over the coming years. Cancer remains a leading cause of mortality worldwide, and there is a substantial unmet medical need for more effective treatments. Gene therapy, including the use of viral vectors and plasmid DNA, holds promise as a novel approach to targeting and treating various types of cancer. Ongoing research in oncology has led to a deeper understanding of the genetic and molecular basis of cancer. This knowledge has paved the way for the development of gene therapies that can target specific genetic mutations and pathways responsible for cancer growth. Gene therapies can be designed to target cancer cells specifically, minimizing damage to healthy tissues and reducing side effects compared to traditional chemotherapy and radiation therapy. This targeted approach is particularly attractive for treating cancer.

Regional Insights

The North America region dominates the Global Viral Vector and Plasmid DNA Manufacturing Market in 2022. North America, particularly the United States, has a well-developed and mature biopharmaceutical industry. The region is home to numerous biotechnology and pharmaceutical companies with extensive experience in research, development, and manufacturing of biologics, including viral vectors and plasmid DNA. North America has been at the forefront of gene therapy research and development. The United States has seen significant investment and progress in the field, leading to a higher number of clinical trials and commercialization efforts involving viral vectors and plasmid DNA. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) have provided clear pathways and guidance for the development and approval of gene therapies. This regulatory clarity has attracted investments and encouraged companies to pursue clinical development and manufacturing activities in the region.

Key Market Players

Oxford Biomedica PLC

Cognate BioServices Inc.

Cell and Gene Therapy Catapult Ltd.

FinVector Vision Therapies

Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)

SIRION Biotech GmbH

Merck KGaA Inc.

Thermo Fisher Scientific

Uniqure NV

Catalent Inc.

Report Scope:

In this report, the Global Viral Vector and Plasmid DNA Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:

  • Plasmid DNA
  • Viral Vector
  • Non-viral Vector

Viral Vector and Plasmid DNA Manufacturing Market, By Application:

  • Cancer
  • Genetic Disorder
  • Infectious Disease
  • Other Applications

Global Viral Vector and Plasmid DNA Manufacturing Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Viral Vector and Plasmid DNA Manufacturing Market.

Available Customizations:

  • Global Viral Vector and Plasmid DNA Manufacturing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Viral Vector and Plasmid DNA Manufacturing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Plasmid DNA, Viral Vector, and Non-viral Vector)
    • 5.2.2. By Application (Cancer, Genetic Disorder, Infectious Disease, and Other Applications)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Market Map

6. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
    • 6.3.2. India Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Australia Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
    • 6.3.4. Japan Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Product Type
        • 6.3.4.2.2. By Application
    • 6.3.5. South Korea Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Product Type
        • 6.3.5.2.2. By Application

7. Europe Viral Vector and Plasmid DNA Manufacturing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
    • 7.3.3. Spain Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
    • 7.3.5. United Kingdom Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application

8. North America Viral Vector and Plasmid DNA Manufacturing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
    • 8.3.2. Mexico Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Canada Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application

9. South America Viral Vector and Plasmid DNA Manufacturing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application

10. Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Viral Vector and Plasmid DNA Manufacturing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Viral Vector and Plasmid DNA Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Oxford Biomedica PLC
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Cognate BioServices Inc.
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Cell and Gene Therapy Catapult Ltd.
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. FinVector Vision Therapies
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. SIRION Biotech GmbH
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Merck KGaA Inc.
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Thermo Fisher Scientific Inc.
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Uniqure NV
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10. Catalent Inc.
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis

17. Strategic Recommendations

About Us & Disclaimer